Clazakizumab, an anti-IL-6 monoclonal antibody for the treatment of rheumatoid arthritis, meets primary endpoint in follow-on Phase 2b clinical trial
5 May 2015 | By Victoria White
Clazakizumab has met its primary endpoint in a follow-on Phase 2b clinical trial in adults with moderate to severe rheumatoid arthritis...